People with type 2 diabetes who engage in just two workouts a week are 33% less likely to die from heart complications, a new study has revealed. A team of researchers has found that exercising only ...

Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.

GLP-1 medications like semaglutide and tirzepatide are helping people shed weight and keep it off. But let’s be clear: These aren’t miracle pills you buy off ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date.

President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...

Smoothie King features a GLP-1 support menu crafted by an expert team of registered dietitians to give you the support you ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Cigna has sold its Medicare businesses and slashed the number of people it covers in its ACA plans by more than half.

Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...